Time until definitive deterioration in patient-reported outcomes with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib who harbor KIT exon 11 + 17/18 mutations: Exploratory analysis from INTRIGUE

Pharmacokinetics and Safety of Ripretinib in Participants with Hepatic Impairment: A Phase 1 Study

Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE

INSIGHT: A Phase III Trial of Ripretinib Versus Sunitinib in Patients with Advanced GIST with KIT Exon 11 and Exon 17/18 Mutations Who Were Previously Treated with Imatinib

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations

Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: final analyses from INTRIGUE (Slides)

Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: final analyses from INTRIGUE (Poster)

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

INSIGHT: A Phase 3, Randomized, Open-Label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor Previously Treated with Imatinib with Kit Exon 11 + 17/18 Mutations

Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.